Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Optimizing Hepatitis C Treatment in a Canadian Population
EF 2017-18
Résumé
Chronic Hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver disease, making it a leading indicator for liver transplantation. In Canada, the conventional therapy for HCV infection, pegylated interferon and ribavirin (Peg-IFN/RBV), leads to viral clearance in only 40-50% of patients. Since 2011, several drugs that offer improved response rates, collectively called direct-acting antivirals, have been approved for the treatment of HCV. However, these new treatments are more expensive and some are associated with a higher rates of antiviral drug resistance, which can result in unsuccessful treatment. RBV is still used to improve outcomes for difficult to treat patients. Previous studies have shown that genetic variants in interleukin 2B and interferon lambda 4 (IL28B/IFNL4) can predict which patients are likely to respond to the standard Peg-IFN HCV therapy, while variants in inosine triphosphatase (ITPA) and some solute carrier genes (SLC28A3 and SLC29A1) can predict which patients are likely to experience the most treatment-limiting ADR (RBV-induced anemia). We aim to validate known genetic associations, and uncover new genetic associations, for both treatment response and risk of anemia in a Canadian multiethnic cohort of 230 HCV patients who have received RBV-based treatments, by assessing 750,000 variants across the genome. These genetic data will be used to personalize HCV therapy in Canadian patients/strong> to ensure patients receive the therapy that they are most likely to respond to and least likely to experience anemia.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386365
Name
Lin Jennifer
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimizing Hepatitis C Treatment in a Canadian Population
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anemia; Hepatitis C; Pharmacogenomics; Prediction Model; Ribavirin
Abstract
Chronic Hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver disease, making it a leading indicator for liver transplantation. In Canada, the conventional therapy for HCV infection, pegylated interferon and ribavirin (Peg-IFN/RBV), leads to viral clearance in only 40-50% of patients. Since 2011, several drugs that offer improved response rates, collectively called direct-acting antivirals, have been approved for the treatment of HCV. However, these new treatments are more expensive and some are associated with a higher rates of antiviral drug resistance, which can result in unsuccessful treatment. RBV is still used to improve outcomes for difficult to treat patients. Previous studies have shown that genetic variants in interleukin 2B and interferon lambda 4 (IL28B/IFNL4) can predict which patients are likely to respond to the standard Peg-IFN HCV therapy, while variants in inosine triphosphatase (ITPA) and some solute carrier genes (SLC28A3 and SLC29A1) can predict which patients are likely to experience the most treatment-limiting ADR (RBV-induced anemia). We aim to validate known genetic associations, and uncover new genetic associations, for both treatment response and risk of anemia in a Canadian multiethnic cohort of 230 HCV patients who have received RBV-based treatments, by assessing 750,000 variants across the genome. These genetic data will be used to personalize HCV therapy in Canadian patients/strong> to ensure patients receive the therapy that they are most likely to respond to and least likely to experience anemia.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lin, Jennifer
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~